IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma

被引：54

作者：

Kishi, Seiji ^{[1
]}

Minato, Masanori ^{[1
]}

Saijo, Atsuro ^{[2
]}

Murakami, Naoka ^{[3
]}

Tamaki, Masanori ^{[1
]}

Matsuura, Motokazu ^{[1
]}

Murakami, Taichi ^{[1
]}

Nagai, Kojiro ^{[1
]}

Abe, Hideharu ^{[1
]}

Nishioka, Yasuhiko ^{[2
]}

Doi, Toshio ^{[1
]}

机构：

[1] Tokushima Univ, Grad Sch Biomed Sci, Dept Nephrol, Tokushima, Japan

[2] Tokushima Univ, Grad Sch Biomed Sci, Dept Resp Med & Rheumatol, Tokushima, Japan

[3] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Renal Div, Boston, MA USA

来源：

INTERNAL MEDICINE | 2018年 / 57卷 / 09期

关键词：

nivolumab; onconephrology; immune-related adverse events (irAEs); glomerular injury; IgA nephropathy; IMMUNE CHECKPOINT INHIBITORS; CANCER; MANAGEMENT; TOXICITIES; BLOCKADE; TRIAL;

D O I：

10.2169/internalmedicine.9814-17

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Immune checkpoint inhibitors (ICIs) are becoming a common and important cancer therapy. ICIs are associated with a unique category of side effects, termed immune-related adverse events (irAEs). We herein report the case of a 72-year-old man with postoperative recurrence of lung squamous cell carcinoma who was treated with nivolumab and who developed proteinuria and a worsening kidney function. A kidney biopsy revealed IgA nephropathy. After drug withdrawal, the proteinuria improved and the deterioration of the patient's renal function was halted. Although renal irAEs are considered to be rare and glomerulonephritis is not typical presentation, physicians need to pay more attention to renal irAEs and glomerular injury.

引用

页码：1259 / 1263

页数：5

共 17 条

[1] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Brahmer, Julie
Reckamp, Karen L.
Baas, Paul
Crino, Lucio
Eberhardt, Wilfried E. E.
Poddubskaya, Elena
Antonia, Scott
Pluzanski, Adam
Vokes, Everett E.
Holgado, Esther
Waterhouse, David
Ready, Neal
Gainor, Justin
Aren Frontera, Osvaldo
Havel, Libor
Steins, Martin
Garassino, Marina C.
Aerts, Joachim G.
Domine, Manuel
Paz-Ares, Luis
Reck, Martin
Baudelet, Christine
Harbison, Christopher T.
Lestini, Brian
Spigel, David R.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) : 123 - 135
[2] Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
Champiat, S.
Lambotte, O.
Barreau, E.
Belkhir, R.
Berdelou, A.
Carbonnel, F.
Cauquil, C.
Chanson, P.
Collins, M.
Durrbach, A.
Ederhy, S.
Feuillet, S.
Francois, H.
Lazarovici, J.
Le Pavec, J.
De Martin, E.
Mateus, C.
Michot, J. -M.
Samuel, D.
Soria, J. -C.
Robert, C.
Eggermont, A.
Marabelle, A.
[J]. ANNALS OF ONCOLOGY, 2016, 27 (04) : 559 - 574
[3] Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
Cortazar, Frank B.
Marrone, Kristen A.
Troxell, Megan L.
Ralto, Kenneth M.
Hoenig, Melanie P.
Brahmer, Julie R.
Le, Dung T.
Lipson, Evan J.
Glezerman, Ilya G.
Wolchok, Jedd
Cornell, Lynn D.
Feldman, Paul
Stokes, Michael B.
Zapata, Sarah A.
Hodi, F. Stephen
Ott, Patrick A.
Yamashita, Michifumi
Leaf, David E.
[J]. KIDNEY INTERNATIONAL, 2016, 90 (03) : 638 - 647
[4] Anti-CTLA4 Antibody-Induced Lupus Nephritis.
Fadel, Fouad
El Karoui, Khalil
Knebelmann, Bertrand
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (02) : 211 - 212
[5] Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial
Fellstroem, Bengt C.
Barratt, Jonathan
Cook, Heather
Coppo, Rosanna
Feehally, John
de Fijter, Johan W.
Floege, Juergen
Hetzel, Gerd
Jardine, Alan G.
Locatelli, Francesco
Maes, Bart D.
Mercer, Alex
Ortiz, Fernanda
Praga, Manuel
Sorensen, Soren S.
Tesar, Vladimir
Del Vecchio, Lucia
[J]. LANCET, 2017, 389 (10084) : 2117 - 2127
[6] Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors A Review
Friedman, Claire F.
Proverbs-Singh, Tracy A.
Postow, Michael A.
[J]. JAMA ONCOLOGY, 2016, 2 (10) : 1346 - 1353
[7] Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
Horvat, Troy Z.
Adel, Nelly G.
Thu-Oanh Dung
Momtaz, Parisa
Postow, Michael A.
Callahan, Margaret K.
Carvajal, Richard D.
Dickson, Mark A.
D'Angelo, Sandra P.
Woo, Kaitlin M.
Panageas, Katherine S.
Wolchok, Jedd D.
Chapman, Paul B.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (28) : 3193 - +
[8] Renal effects of immune checkpoint inhibitors
Izzedine, Hassan
Mateus, Christine
Boutros, Celine
Robert, Caroline
Rouvier, Philippe
Amoura, Zahir
Mathian, Alexis
[J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 (06) : 936 - 942
[9] Nivolumab-associated acute glomerulonephritis: a case report and literature review
Jung, Kyungsuk
Zeng, Xu
Bilusic, Marijo
[J]. BMC NEPHROLOGY, 2016, 17 : 1 - 6
[10] Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship
Molina, Julian R.
Yang, Piii G.
Cassivi, Stephen D.
Schild, Steven E.
Adjei, Alex A.
[J]. MAYO CLINIC PROCEEDINGS, 2008, 83 (05) : 584 - 594

← 1 2 →